Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cecile Magis-Escurra

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
The Journal of Infection|July 2, 2020
The role of volatile organic compounds as predictors of treatment response in drug susceptible TB patients: An initial proof of concept studyRosarito Coronel Teixeira, Sandra Gonzalez, Myrian Román, et al.
The European Respiratory Journal|April 20, 2019
Outcomes of hypertonic saline inhalation as a treatment modality in nontuberculous mycobacterial pulmonary diseaseAnne Huiberts, Sanne M H Zweijpfenning, Lian J Pennings, et al.
Clinical Pharmacokinetics|February 22, 2021
A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary TuberculosisStijn W van Beek, Rob Ter Heine, Jan-Willem C Alffenaar, et al.
The Lancet. Respiratory Medicine|February 4, 2018
Pound foolish and penny wise-when will dosing of rifampicin be optimised?Cecile Magis-Escurra, Richard M Anthony, Adri G M van der Zanden, et al.
Chest|December 1, 2023
Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized TrialSanne M H Zweijpfenning, Rob Aarnoutse, Martin J Boeree, et al.
Plos One|September 17, 2010
The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosisDick van Soolingen, Rogelio Hernandez-Pando, Hector Orozco, et al.
The Journal of Infection|January 10, 2013
Prevalence of nontuberculous mycobacteria in COPD patients with exacerbationsWouter Hoefsloot, Jakko van Ingen, Cecile Magis-Escurra, et al.
Clinical Pharmacokinetics|April 3, 2021
Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary TuberculosisStijn W van Beek, Rob Ter Heine, Jan-Willem C Alffenaar, et al.
The Journal of Antimicrobial Chemotherapy|August 14, 2025
Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodologyIsabella van der Feltz, Haini Wen, Rob E Aarnoutse, et al.
ERJ Open Research|November 25, 2021
Treatment of severe <i>Mycobacterium avium</i> complex pulmonary disease with adjunctive amikacin and clofazimine <i>versus</i> standard regimen alone: a retrospective studySanne M H Zweijpfenning, Stephan E P Kops, Martin J Boeree, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
The Journal of Infection|July 2, 2020
The role of volatile organic compounds as predictors of treatment response in drug susceptible TB patients: An initial proof of concept studyRosarito Coronel Teixeira, Sandra Gonzalez, Myrian Román, et al.
The European Respiratory Journal|April 20, 2019
Outcomes of hypertonic saline inhalation as a treatment modality in nontuberculous mycobacterial pulmonary diseaseAnne Huiberts, Sanne M H Zweijpfenning, Lian J Pennings, et al.
Clinical Pharmacokinetics|February 22, 2021
A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary TuberculosisStijn W van Beek, Rob Ter Heine, Jan-Willem C Alffenaar, et al.
The Lancet. Respiratory Medicine|February 4, 2018
Pound foolish and penny wise-when will dosing of rifampicin be optimised?Cecile Magis-Escurra, Richard M Anthony, Adri G M van der Zanden, et al.
Chest|December 1, 2023
Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized TrialSanne M H Zweijpfenning, Rob Aarnoutse, Martin J Boeree, et al.
Plos One|September 17, 2010
The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosisDick van Soolingen, Rogelio Hernandez-Pando, Hector Orozco, et al.
The Journal of Infection|January 10, 2013
Prevalence of nontuberculous mycobacteria in COPD patients with exacerbationsWouter Hoefsloot, Jakko van Ingen, Cecile Magis-Escurra, et al.
Clinical Pharmacokinetics|April 3, 2021
Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary TuberculosisStijn W van Beek, Rob Ter Heine, Jan-Willem C Alffenaar, et al.
The Journal of Antimicrobial Chemotherapy|August 14, 2025
Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodologyIsabella van der Feltz, Haini Wen, Rob E Aarnoutse, et al.
ERJ Open Research|November 25, 2021
Treatment of severe <i>Mycobacterium avium</i> complex pulmonary disease with adjunctive amikacin and clofazimine <i>versus</i> standard regimen alone: a retrospective studySanne M H Zweijpfenning, Stephan E P Kops, Martin J Boeree, et al.
Pageof 6